Capricor Therapeutics (CAPR) Misses Q4 EPS by 11c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.62), $0.11 worse than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• enVVeno Medical (NVNO) files $100M mixed shelf
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises